Filing Flows › 8-K events › MSG Rangers
MSG Rangers: entry into a material definitive agreement
Form 8-K filed Oct 27, 2026 · items 1.01, 5.02, 5.03, 8.01
What the filing says
On October 26, 2026, MSG Knickerbockers Corp. (formerly Madison Square Garden Sports Corp. and referred herein as “MSG Knicks”) effected the distribution (the “Distribution”) of all of the issued and outstanding shares of the common stock of MSG Rangers Corp. (formerly MSGS Spinco, Inc., and referred to herein as the “
Read the filing on SEC EDGAR →
What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 5.02: −0.1% next session across 39,174. Item 5.03: +0.1% next session across 5,869. Every item ranked →
What this kind of filing means
Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.
Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.
MSG Rangers at a glance
MSG Rangers, Q1 FY27: revenue $14.1M (+3% year over year), operating margin -167.4%. The chart follows the revenue to costs, profit and cash.
MSG Rangers: every quarter, Q/Q and Y/Y, holders and guidance →
Other recent board changes
- Roku Nov 6, 2026
- Bowman Consulting Group Nov 6, 2026
- GBT Technologies Nov 5, 2026
- Transportation & Logistics Systems Nov 5, 2026
- Wendy's Nov 5, 2026
- Liberty Media Nov 5, 2026
- First Capital Nov 5, 2026
- Brady Nov 5, 2026
- Borealis Foods Nov 4, 2026
- Processa Pharmaceuticals Nov 4, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.